Exploring Protalix BioTherapeutics, Inc. (PLX) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Protalix BioTherapeutics (PLX) and, more importantly, why? As of April 16, 2025, the share price stands at $2.58, a significant 124.35% increase from $1.15 on April 17, 2024 [1]. Institutional investors hold a total of 4,963,946 shares [1]. Are these strategic moves driven by the company's strong fiscal year 2024, which saw record revenues of $53.0 million, a 31% increase from 2023, or perhaps by key developments like the successful Phase I trial for PRX-115 [2]? Join us as we delve into the investor profile of Protalix, uncovering the major players and the factors influencing their investment decisions.

Protalix BioTherapeutics, Inc. (PLX) Who Invests in Protalix BioTherapeutics, Inc. (PLX) and Why?

Understanding the investor profile of Protalix BioTherapeutics, Inc. (PLX) provides valuable insights into the market's perception of the company. Investors are drawn to Protalix for a variety of reasons, reflecting the company's unique position in the biopharmaceutical industry.

Key Investor Types:

The investor base of Protalix BioTherapeutics, Inc. (PLX) is composed of a mix of retail investors, institutional investors, and hedge funds.

• Retail Investors: These individual investors often focus on growth potential and may be drawn to Protalix due to its innovative work in the biopharmaceutical sector.
• Institutional Investors: These include investment firms, mutual funds, and pension funds that invest on behalf of their clients. Institutional investors typically conduct in-depth research before investing.
• Hedge Funds: These funds tend to seek short-term gains through active trading strategies. They might invest in Protalix based on specific events or market trends.

Investment Motivations:

Investors are attracted to Protalix BioTherapeutics, Inc. (PLX) for several key reasons:

• Growth Prospects: The biopharmaceutical industry offers substantial growth opportunities, particularly for companies developing innovative treatments.
• Market Position: Protalix's expertise in plant cell-based protein expression technology gives it a competitive edge in producing complex therapeutic proteins.

Investment Strategies:

The strategies employed by investors in Protalix BioTherapeutics, Inc. (PLX) can vary widely:

• Long-Term Holding: Some investors adopt a long-term perspective, holding shares based on the belief that the company's value will increase over time due to successful drug development and market expansion.
• Short-Term Trading: Other investors engage in short-term trading, capitalizing on price fluctuations driven by news events, clinical trial results, or market sentiment.
• Value Investing: Value investors seek to identify undervalued companies with strong fundamentals. They may view Protalix as a value investment if they believe the company's stock price does not fully reflect its intrinsic value.

Here is a sample table illustrating potential investor profiles and their investment approaches:

Understanding these diverse investment strategies and motivations can provide a more nuanced view of Protalix BioTherapeutics, Inc. (PLX) within the investment community. For further insights into the company's mission, vision, and core values, refer to: Mission Statement, Vision, & Core Values of Protalix BioTherapeutics, Inc. (PLX).

Protalix BioTherapeutics, Inc. (PLX) Institutional Ownership and Major Shareholders of Protalix BioTherapeutics, Inc. (PLX)

Institutional ownership in Protalix BioTherapeutics, Inc. (PLX) reflects the extent to which large financial entities hold shares in the company. Examining the identities and actions of these major shareholders can provide insights into market sentiment and potential stock performance. As of April 2025, 54 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 4,963,946 shares.

Here's a breakdown of institutional ownership in Protalix BioTherapeutics, Inc. (PLX):

• Institutional Ownership: 5.72%
• Total Value of Holdings: $12 million

Major shareholders in Protalix BioTherapeutics, Inc. (PLX) include:

• Renaissance Technologies LLC
• Northern Trust Corp
• Millennium Management LLC
• Gsa Capital Partners LLP
• Stratos Wealth Partners, LTD.
• BlackRock, Inc.
• AUERX - Auer Growth Fund
• Bridgeway Capital Management Inc
• BRSIX - Ultra-Small Company Market Fund Class N
• Morgan Stanley

Below is a detailed list of institutional holders, reflecting their positions as of December 31, 2024:

Recent changes in institutional positions reveal shifts in investor confidence:

• Northern Trust Corp increased its holdings significantly, with a change of 1299.365%.
• Renaissance Technologies LLC increased its shares by 16.958%.
• However, Gsa Capital Partners LLP decreased its position by -29.747%.

Institutional investors play a crucial role in influencing a company's stock price and strategy. Their actions can drive trading volume and impact market perception. For Protalix BioTherapeutics, Inc. (PLX), the overall institutional ownership suggests moderate institutional interest. Notably, Protalix BioTherapeutics, Inc. (PLX) finds itself in an enviable position as of early 2025, with two approved products generating revenues and a pipeline with multiple candidates in development.

Furthermore, Protalix has a strong balance sheet with over $27 million in cash and has eliminated all debt. The company's strategic updates are closely watched by investors, as evidenced by their participation in conferences such as the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025.

For additional insights into the financial health of Protalix BioTherapeutics, Inc. (PLX), consider exploring: Breaking Down Protalix BioTherapeutics, Inc. (PLX) Financial Health: Key Insights for Investors

Protalix BioTherapeutics, Inc. (PLX) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Protalix BioTherapeutics, Inc. (PLX) provides valuable insights into the company's stability, growth potential, and strategic direction. Institutional ownership, major shareholders, and recent trading activities can significantly influence stock movements and corporate decisions. As of April 2025, a number of institutional investors and key individuals hold significant stakes in Protalix.

Institutional Ownership:

Protalix BioTherapeutics, Inc. has a notable presence of institutional owners and shareholders. According to recent filings with the Securities and Exchange Commission (SEC), as of April 18, 2025, there are 54 institutional owners and shareholders holding a total of 4,963,946 shares. This accounts for approximately 6.36% of the company's shares outstanding, excluding those held by insiders.

Key institutional investors include:

• Renaissance Technologies LLC: Holding 1,118,000 shares as of December 31, 2024, marking a 16.958% increase in their holdings.
• Northern Trust Corp: Holding 731,742 shares as of December 31, 2024, a significant increase of 1299.365%.
• Millennium Management LLC: Holding 387,921 shares as of December 31, 2024, with a 3.79% increase.
• Gsa Capital Partners Llp: Holding 305,749 shares as of December 31, 2024, reflecting a -29.747% change.
• BlackRock, Inc.: Holding 224,657 shares as of December 31, 2024.
• Bridgeway Capital Management, Llc: Holding 181,400 shares as of December 31, 2024.
• Morgan Stanley: Holding 170,216 shares as of December 31, 2024.

These institutions play a crucial role in shaping market sentiment and influencing the stock's volatility. Their investment decisions are often based on thorough research and analysis, providing a degree of stability and confidence for other investors.

Major Individual Shareholders:

Besides institutional investors, several individual shareholders also hold significant equity in Protalix BioTherapeutics, Inc. These include:

• Dror Bashan: Holding 3.099% of equities, valued at approximately $5 million.
• Marius Nacht: Holding 3% of equities, also valued at around $5 million.

Recent Moves and Insider Activity:

Recent insider trading activities reveal insights into the perspectives of the company's officers. For instance:

• Eyal Rubin (Officer): Acquired 99,010 indirect shares as of September 23, 2024, holding a total of 669,010 shares.
• Dror Bashan (Officer): Acquired 263,960 indirect shares as of April 1, 2024, holding 2,149,418 shares.

These acquisitions may reflect the officers' confidence in the company's future prospects.

Fund Sentiment Score:

The Fund Sentiment Score, which assesses how actively funds are buying a stock, uses a quantitative model to identify companies with high levels of institutional accumulation. This score considers the increase in disclosed owners and changes in portfolio allocations, providing a metric from 0 to 100, where higher numbers indicate greater accumulation.

Institutional Buying and Selling Trends:

Analyzing institutional buying and selling activities provides a clearer picture of market sentiment towards Protalix. Recent data indicates:

• Total institutional inflows over the last 12 months: $2.99 million.
• Total institutional outflows over the last 12 months: $412.95K.
• Number of institutional buyers: 14.
• Number of institutional sellers: 7.

Significant increases in shareholdings have been noted by several institutions:

• Northern Trust Corp increased its shares by 1,299.4%.
• Jane Street Group LLC increased its shares by 147.2%.
• Renaissance Technologies LLC increased its shares by 17.0%.

Activist Investors:

Activist investors can significantly influence a company's direction through their involvement. However, recent data shows that Whitebox Advisors LLC, which previously held 2,816,108 shares, reduced its stake to 0 as of October 25, 2024.

Ownership Structure Breakdown:

The general ownership structure of Protalix BioTherapeutics, Inc. is composed of:

• General Public: 69.2%
• Individual Insiders: 10.7%
• Hedge Funds: 10.4%
• Institutions: 6.58%

Impact on Company Decisions and Stock Movements:

Major shareholders and institutional investors can influence company decisions through voting rights and direct engagement with the management. Their investment activities can also drive stock price volatility, especially when large stakes are bought or sold.

For instance, a shareholder investigation was announced by Kaskela Law LLC in September 2024, concerning potential breaches of fiduciary duties, which coincided with a decline in the stock value from approximately $3.25 to below $1.25 per share since May 2023.

Additional Resources:

For more detailed information on Protalix BioTherapeutics, Inc., you can explore:

• The company's investor relations page.
• SEC filings for institutional holdings and insider trading activities.
• Financial news and analysis platforms for up-to-date information.

Also, consider reading about the company's history, mission, and business model: Protalix BioTherapeutics, Inc. (PLX): History, Ownership, Mission, How It Works & Makes Money

Understanding these factors provides a comprehensive view of investor confidence and potential impacts on Protalix BioTherapeutics, Inc.'s strategic initiatives and stock performance.

Protalix BioTherapeutics, Inc. (PLX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Protalix BioTherapeutics, Inc. (PLX) can offer valuable insights into the company's current standing and future prospects. Analyzing major shareholder activity, recent market responses, and analyst perspectives provides a comprehensive view of PLX's financial landscape.

Assessing the overall sentiment of major shareholders toward Protalix BioTherapeutics, Inc. (PLX) is crucial for understanding the stock's potential stability and growth. While specific, real-time sentiment analysis of major shareholders can fluctuate, observing significant changes in their positions—increases or decreases in holdings—can indicate their confidence in the company's direction. Positive sentiment generally correlates with increased investment, whereas negative sentiment may lead to divestment. Keep an eye on these indicators to gauge the prevailing attitude among key investors.

The stock market's reaction to changes in ownership or substantial investor moves can significantly impact Protalix BioTherapeutics, Inc. (PLX). For instance, a large institutional investor increasing their stake may drive the stock price up, reflecting increased confidence. Conversely, a major sell-off could trigger a price decline. Monitoring these market reactions provides insight into how the broader investment community perceives the value and prospects of PLX. Consider these points:

• Sudden Price Spikes: Often linked to positive news or increased institutional buying.
• Price Drops: May indicate concerns over financial performance or strategic direction.
• Trading Volume: Higher volume during these events can amplify price movements.

Analyst perspectives play a pivotal role in shaping investor understanding of Protalix BioTherapeutics, Inc. (PLX). Analysts offer insights based on thorough research and financial modeling, which can influence investor sentiment and market behavior. Their reports typically cover aspects such as:

• Future Growth Potential: Assessments of PLX's pipeline and market opportunities.
• Financial Health: Analysis of balance sheets, income statements, and cash flow.
• Risk Factors: Identification of potential challenges and uncertainties.
• Price Targets: Projections of where the stock price could move based on their analysis.

For example, analysts might focus on the potential impact of key investors on Protalix BioTherapeutics, Inc. (PLX)'s future, particularly concerning strategic decisions or financial stability. If a major investor is known for supporting long-term growth, analysts might view their increased stake as a positive signal for the company's strategic direction. Conversely, if an investor with a history of short-term gains takes a significant position, analysts might caution against potential volatility. This information is usually available through financial news outlets, analyst reports, and investor relations updates from Protalix BioTherapeutics, Inc. (PLX) itself.

To provide a clearer picture, here’s an example of how different factors can interplay:

Understanding these dynamics is essential for anyone looking to invest in or monitor Protalix BioTherapeutics, Inc. (PLX). These factors collectively shape the market's perception and the stock's performance.

To gain more historical context and information about Protalix BioTherapeutics, Inc. (PLX), you can refer to this resource: Protalix BioTherapeutics, Inc. (PLX): History, Ownership, Mission, How It Works & Makes Money